Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer (PASCART)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00724581|
Recruitment Status : Unknown
Verified July 2008 by Aarhus University Hospital.
Recruitment status was: Not yet recruiting
First Posted : July 29, 2008
Last Update Posted : July 29, 2008
Patients undergoing lung resection due to pulmonary cancer can be compromised in their postoperative period due to atrial fibrillation.
A retrospective analysis performed at our institution indicates that 30 % of the population develope atrial fibrillation in the postoperative period.
Amiodarone is known to diminish the occurence of postoperative atrial fibrillation after heart surgery, why this drug is chosen as a prophylactic agent for the mentioned population.
Amiodarone is administrated twice a day for 5 days at a dose of 600 mg oral treatment after an initial loading bolus og 300 mg intravenously.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Drug: Amiodarone||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||275 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial|
|Study Start Date :||August 2008|
|Estimated Primary Completion Date :||August 2009|
|Estimated Study Completion Date :||December 2009|
intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
- Free of atrial fibrillation [ Time Frame: 31082009 ]
- Cost-benefit analysis of amiodarone prophylactic [ Time Frame: 31082009 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00724581
|Contact: Lars R Zebis, MD||+45 firstname.lastname@example.org|
|Contact: Thomas Decker, MD||+45 89495566|
|Aarhus University Hospital, Skejby||Not yet recruiting|
|Aarhus, Denmark, DK-8200|
|Contact: Lars R Zebis, MD, Ph.D. +45 89495566 email@example.com|
|Contact: Thomas D Christensen, MD, Ph.D. +45 89495566|
|Principal Investigator: Lars R Zebis, MD, Ph.D.|
|Principal Investigator:||Lars R Zebis, MD, Ph.D.||Aarhus University Hospital Skejby|